Back to today’s briefing

Story perspectives

GSK and Hengrui Partner for $12 Billion Medicine Breakthrough

7/29/2025

50 3

Summary

Story summary

GSK plc is making waves in the pharmaceutical world by teaming up with Hengrui Pharma to create up to 12 groundbreaking medicines, including the promising COPD treatment, HRS-9821. With an initial investment of $500 million and potential future payments soaring to $12 billion, this partnership positions GSK to lead the charge in innovation while Hengrui spearheads Phase I trials.

History

Historical Context

In 2000, the FDA approved the first inhaled corticosteroid for asthma, transforming respiratory care. GSK, a leading pharmaceutical company, has since invested $500 million with Hengrui Pharma to develop 12 new medicines, including HRS-9821 for COPD. This partnership highlights a trend towards international collaboration in drug development, with potential future payments reaching $12 billion, emphasizing the industry's focus on innovation.

1 of 2

Story summary

GSK plc is making waves in the pharmaceutical world by teaming up with Hengrui Pharma to create up to 12 groundbreaking medicines, including the promising COPD treatment, HRS-9821. With an initial investment of $500 million and potential future payments soaring to $12 billion, this partnership positions GSK to lead the charge in innovation while Hengrui spearheads Phase I trials.

1 / 2